MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/cpdd.1463

Медицинская библиотека · Clinical pharmacology in drug development · 2024

Bioequivalence and Safety of Generic Glecaprevir/Pibrentasvir Compared to a Branded Product: A Randomized, Crossover Study in Healthy Volunteers.

Noskov Sergei, Parulya Olesya, Lutskova Lyudmila, Arefeva Anna, Protsenko Ekaterina, Banko Veniamin, Radaeva Kseniia, Matvienko Iuliia, Gefen Maria, Karnakova Polina, Knyazeva Alina, Komarov Timofey, Archakova Olga, Shohin Igor

СтатьяРандомизированное исследованиеСравнительное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

This was an open-label, randomized, single-dose, 2-period, crossover clinical trial with an adaptive design to evaluate the bioequivalence and comparative pharmacokinetics of generic glecaprevir/pibrentasvir versus the brand name product in healthy White male and female volunteers under fed conditions. Safety profiles were also assessed. A total of 56 healthy adult volunteers were enrolled and randomly assigned in a 1:1 ratio to receive a single dose of either the generic or reference formulation. After a 7-day washout period, subjects received the alternate product. Blood samples were collected at pre-specified time points up to 48 hours post-dosing. Plasma concentrations of glecaprevir and pibrentasvir were determined using a validated high-performance liquid chromatography-tandem mass spectrometry method. The geometric mean ratios of the test to the reference formulation for maximum plasma concentration (Cmax) and area under the concentration-time curve from drug administration to the last measurable concentration (AUC0-t) fell within the predefined bioequivalence range of 80%-125%. Both formulations demonstrated comparable pharmacokinetic profiles for glecaprevir and pibrentasvir, and can be considered bioequivalent. No adverse events were reported, and both formulations were well tolerated by all participants.

Для цитирования: Noskov Sergei, Parulya Olesya, Lutskova Lyudmila, Arefeva Anna, Protsenko Ekaterina, Banko Veniamin, Radaeva Kseniia, Matvienko Iuliia, Gefen Maria, Karnakova Polina, Knyazeva Alina, Komarov Timofey, Archakova Olga, Shohin Igor. Bioequivalence and Safety of Generic Glecaprevir/Pibrentasvir Compared to a Branded Product: A Randomized, Crossover Study in Healthy Volunteers.. Clinical pharmacology in drug development. 2024. DOI: 10.1002/cpdd.1463.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.